Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non–Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker-Reference-Cited by-同舟云学术

Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non–Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker

Published:2015-09 Issue:5 Volume:16 Page:348-357
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Ramlau Rodryg,Thomas Michael,Novello Silvia,Plummer Ruth,Reck Martin,Kaneko Tomomi,Lau Mike R.,Margetts Jane,Lunec John,Nutt Joyce,Scagliotti Giorgio V.

Funder

GlaxoSmithKline

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference37 articles.

1. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity;Eheman;Cancer,2012

2. International Agency for Research on Cancer. World Health Organization. GLOBOCAN 2012. Estimated cancer incidence, mortality, and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 18 August 2014.

3. The changing pattern of non-small cell lung cancer between the 90th and 2000th decades;Montesinos;Open Respir Med J,2011

4. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non–small-cell lung cancer;Azzoli;J Clin Oncol,2009

5. The role of histology with common first-line regimens for advanced non–small-cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial;Scagliotti;J Thorac Oncol,2009

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment;Molecules;2023-08-30

2. Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives;Cancer Biology & Medicine;2022-12-05

3. Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics;Anti-Cancer Drugs;2022-11-16

4. HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy;OncoTargets and Therapy;2021-11

5. A narrative review of advances in treatment and survival prognosis of HER2-positive malignant lung cancers;Journal of Thoracic Disease;2021-06